(3E)-5-ethoxycarbonyloxycyclooct-3-ene-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: (3E)-5-ethoxycarbonyloxycyclooct-3-ene-1-carboxylic acid
• 化学式: C₁₂H₁₈O₅
• 分子量: 242.27
• InChiKey: SAVGBDUWIUEPDV-XVNBXDOJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] ACTIVATABLE LIPOSOMES<br/>[FR] LIPOSOME POUVANT ÊTRE ACTIF
  申请人：TAGWORKS PHARMACEUTICALS B V

  公开号：WO2014081299A1

  公开（公告）日：2014-05-30

  Disclosed are reactive liposome, comprising a lipid bilayer enclosing a cavity, wherein the bilayer comprises a linkage to an eight-membered non-aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The liposomes are use in a kit comprising the liposome linked, directly or indirectly, to a Trigger, and an Activator for the Trigger, wherein the Trigger comprises an eight-membered non-aromatic cyclic alkenylene group, and the Activator comprises a diene.

  揭示了一种反应性脂质体，包括一个脂质双层包裹的腔隙，其中该双层包括与一个含有八个成员的非芳香环烯基基团连接的连接，最好是环辛烯基团，更好是反式环辛烯基团。这些脂质体用于一种工具包，该工具包包括直接或间接地与一个触发器连接的脂质体，以及用于触发器的活化剂，其中触发器包括一个含有八个成员的非芳香环烯基基团，而活化剂包括一个二烯。
• CHEMICALLY CLEAVABLE GROUP
  申请人：TAGWORKS PHARMACEUTICALS B.V.

  公开号：US20150344514A1

  公开（公告）日：2015-12-03

  Disclosed is the use of the reactive components of the inverse electron-demand Diels Alder reaction for chemical masking and unmasking in vitro. This can be applied in complex chemical reactions and, particularly in the synthesis of biomolecules, e.g. on solid supports. The reactive components are a dienophile, particularly a trans-cyclooctene, and a diene, particularly a tetrazine.

  本发明揭示了在体外使用反电子需求Diels-Alder反应的反应组分进行化学遮蔽和解除遮蔽的方法。这可以应用于复杂的化学反应中，特别是在生物分子的合成中，例如在固体支持体上。反应组分是二烯丙烯，特别是反式-环辛烯，和二烯，特别是四唑。
• BIO-ORTHOGONAL DRUG ACTIVATION
  申请人：KONINKLIJKE PHILIPS N.V.

  公开号：US20170143840A1

  公开（公告）日：2017-05-25

  The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.